

83  
Please insert the attached Sequence Listing as new pages --54-72--.

**IN THE CLAIMS**

Please renumber the Claims page from page "54" to --73--.

**IN THE ABSTRACT:**

Please renumber the Abstract page from page "55" to --74--.

**REMARKS**

The specification has been amended to provide sequence identifiers. Applicants' amendments do not introduce new matter.

Also submitted herewith is a paper copy and a computer readable form of a substitute "Sequence Listing" which includes the sequence identifiers requested by the Examiner. The contents of the paper and computer readable copies are the same and include no new matter.

Applicants respectfully request entry of this Second Preliminary Amendment prior to examination of the present application.

Dated: 04/22/02

Thomas W. Brown

Thomas W. Brown  
Registration No. 50,002

MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105  
415.904.6500

## APPENDIX I

### MARKED-UP VERSION OF SPECIFICATION'S REPLACEMENT PARAGRAPHS

The following is a marked-up version of the specification's replacement paragraphs pursuant to 37 C.F.R. §1.121(b) with markings showing changes made herein to the previous version of record of the specification.

#### IN THE SPECIFICATION

On page 8, please delete the paragraphs beginning on line 7 and ending on line 10, and replace with the following paragraphs:

Figure 8 shows the amino acid sequence of human C5a peptide (SEQ ID NO:77) and various smaller portions of the human C5a peptide, specifically, amino acids 1-20 (SEQ ID NO:4), amino acids 13-32 (SEQ ID NO:78), amino acids 21-40 (SEQ ID NO:79), amino acids 31-50 (SEQ ID NO:80), and amino acids 55-74 (SEQ ID NO:6).

Figure 9 (SEQ ID NOS:4 to 6) shows a graph demonstrating the ability of certain synthetic peptides to inhibit the binding of human C5a peptide to human neutrophils.

On page 8, please delete the paragraphs beginning on line 20 and ending on page 9, line 4, and replace with the following paragraphs:

Figure 13 (SEQ ID NO:3) projects the complete amino acid sequence of Human C5a.

Figure 14 (SEQ ID NO:1) projects the complete amino acid sequence of Rat C5a.

Figure 15A (SEQ ID NO:5) projects the "M" fraction of Human C5a as defined by amino acids 21-40 (vis-a-vis the complete amino acid sequence of Human C5a).

Figure 15B (SEQ ID NO:81) presents a variant to the "M" fraction of Human C5a (as compared to Figure 15A) wherein the serine at amino acid 27 is substituted for a cysteine.

Figure 16 (SEQ ID NO:6) projects the "C" fraction of Human C5a as defined by amino acids 55-74 (vis-a-vis the complete amino acid sequence of Human C5a).

Figure 17 (SEQ ID NO:2) projects the "M" fraction of Rat C5a as defined by amino acids 17-36 (vis-a-vis the complete amino acid sequence of Rat C5a).

Figure 18 (SEQ ID NO:75) projects the "C" fraction of Rat C5a as defined by amino acids 58-77 (vis-a-vis the complete amino acid sequence of Rat C5a).

Figure 19 (SEQ ID NO:82) projects the nucleic acid sequence of a Human C5a analog set out in GenBank (NCBI gibbsq 170109).